Anti-CD20 Monoclonal Antibodies Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Anti-CD20 Monoclonal Antibodies Market Size Likely To Evolve From 2025 Through 2034?

The anti-CD20 monoclonal antibodies market size has demonstrated robust growth in recent years. This market is expected to expand from $8.33 billion in 2024 to $9.00 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.9%. Several factors contributed to its historical growth, including the increasing incidence of B-cell malignancies, broader use in autoimmune disease treatments, a rise in FDA and EMA approvals for new anti-CD20 therapies, and the globally expanding geriatric population.

The anti-CD20 monoclonal antibodies market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $12.05 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth can be ascribed to several factors, including a rise in strategic collaborations and licensing agreements, broader application in combination therapies, a growing number of relapsed or refractory cases, increased healthcare spending and accessibility in developing regions, and accelerated development and approvals of biosimilars. Key trends identified for this period encompass progress in monoclonal antibody engineering, the incorporation of anti-CD20 antibodies into combination therapy regimens, technology-enabled customization of cancer treatments, innovations in subcutaneous and long-acting formulations, and breakthroughs in bispecific and next-generation antibodies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25693&type=smp

Which Industry Drivers Are Expected To Accelerate The Anti-CD20 Monoclonal Antibodies Market From 2025 To 2029?

The increasing incidence of autoimmune conditions is anticipated to drive the expansion of the anti-CD20 monoclonal antibodies market moving ahead. These diseases develop when the immune system mistakenly targets the body’s own cells as foreign invaders, initiating an attack. The prevalence of autoimmune disorders is on the rise, attributed to increased exposure to environmental contaminants that can disrupt immune system regulation and provoke assaults on bodily tissues. Anti-CD20 monoclonal antibodies address autoimmune conditions by eradicating B cells, which are responsible for producing autoantibodies and inflammation. They assist in moderating the immune response and alleviating the signs of the disease. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government organization, indicated that in 2022, approximately 514,000 individuals (2.0%) in Australia suffered from rheumatoid arthritis, a systemic autoimmune disorder, affecting 2.5% of females and 1.6% of males. Consequently, the expanding occurrence of autoimmune diseases is fueling the growth of the anti-CD20 monoclonal antibodies market.

What Are The Major Segments Identified In The Anti-CD20 Monoclonal Antibodies Market?

The anti-cd20 monoclonal antibodies market covered in this report is segmented –

1) By Product Type: Rituximab, Obinutuzumab, Ofatumumab, Other Product Types

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (Cll), Rheumatoid Arthritis, Multiple Sclerosis, Pemphigus Vulgaris, Other Applications

5) By End-User: Hospitals, Surgical Centers and Diagnostic Centers, Maternity Centers, Ambulatory Care Centers, Research And Academia, Other End-Users

Subsegments:

1) By Rituximab: Rituxan, Truxima, Ruxience, Reditux

2) By Obinutuzumab: Gazyva, Biosimilar Candidates

3) By Ofatumumab: Arzerra, Kesimpta

4) By Other Product Types: Ublituximab, Veltuzumab, Ocrelizumab, Mosunetuzumab

Which Competitive Trends Are Defining The Anti-CD20 Monoclonal Antibodies Market Structure?

Leading companies in the anti-CD20 monoclonal antibody market are prioritizing the development of advanced products, such as obinutuzumab, to more effectively target resistant or relapsed B-cell malignancies. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody specifically designed to identify and eliminate CD20-positive B cells involved in certain blood cancers and autoimmune diseases. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical company, announced that the US Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) for treating lupus nephritis. This decision follows positive data from the Phase III REGENCY study, which revealed an improved complete renal response (CRR) when combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such a benefit in lupus nephritis, a severe inflammation caused by lupus that can result in kidney failure.

Which Major Industry Participants Are Leading The Anti-CD20 Monoclonal Antibodies Market Growth?

Major companies operating in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anti-cd20-monoclonal-antibodies-global-market-report

How Do Regional Market Performances Compare Within The Anti-CD20 Monoclonal Antibodies Industry?

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-cd20 monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anti-CD20 Monoclonal Antibodies Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25693&type=smp

Browse Through More Reports Similar to the Global Anti-CD20 Monoclonal Antibodies Market 2025, By The Business Research Company

Monoclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Monoclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Polyclonal Antibodies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795